GINGER HOLLOWAY: Open Payments
NPI 1487375622 · ROGERS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$835 in 33 payments from 10 companies in 2025. Trend: 2023 $779 · 2024 $432 · 2025 $835
Food & beverage: $835
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $313 |
| Neurocrine BioSciences, Inc. | 7 | $137 |
| Novo Nordisk Inc | 2 | $136 |
| Vanda Pharmaceuticals Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $40 |
| Alkermes, Inc. | 2 | $37 |
| Lundbeck LLC | 1 | $17 |
| PFIZER INC. | 1 | $17 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: MAVYRET, INGREZZA, Ozempic, VRAYLAR, HETLIOZ, CAPLYTA, VIVITROL, FANAPT.
Industry payments across AR — which companies pay providers there.
